http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018099962-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5305043f754c46243d68ad5d86051d17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a186d8128f8725533beece789f9f8dc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61abb8195410c1a93e0ccb2a4562bdef |
| publicationDate | 2018-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2018099962-A1 |
| titleOfInvention | Naphthyridine compounds, medical combinations and use thereof |
| abstract | This invention involves the field of biomedicine, and reveals naphthyridine compounds, medical combinations and use thereof. The naphthyridine compounds has the structure as shown by Formula (I), or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or their prodrugs. The naphthyridine compounds of this invention has anti-tumor efficacy significantly superior to that of prior art. Moreover, the naphthyridine compounds of this invention can treat diseases mediated by protein kinases. |
| priorityDate | 2016-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 491.